{"disease":{"id":"alt","name":"alt"},"drugs":{"marketed":[{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with other health conditions that put them at increased risk for pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"naloxone-hydrochloride","indication_name":"Pain in patients for whom alternative treatment options are not tolerated","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naloxone Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Opioid receptors (mu, kappa)","drug_class":"Mixed opioid agonist-antagonist with opioid antagonist","quality_score":70,"revenue":null,"mechanism":"Pentazocine is a mixed agonist-antagonist at opioid receptors; naloxone is an opioid antagonist."},{"drug_id":"naloxone-hydrochloride","indication_name":"Pain in patients for whom alternative treatment options would be otherwise inadequate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naloxone Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Opioid receptors (mu, kappa)","drug_class":"Mixed opioid agonist-antagonist with opioid antagonist","quality_score":70,"revenue":null,"mechanism":"Pentazocine is a mixed agonist-antagonist at opioid receptors; naloxone is an opioid antagonist."},{"drug_id":"col","indication_name":"Hand wash for healthcare personnel","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"D-Col Personal Hygiene Convenience Kit","generic_name":"col","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various molecular targets","drug_class":"not well-documented","quality_score":10,"revenue":null,"mechanism":"COL's mechanism of action is not well-documented, but it is believed to target various molecular targets."},{"drug_id":"sacrosidase","indication_name":"Sucrase-isomaltase deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sucraid","generic_name":"SACROSIDASE","company_name":"Qol Medcl","drug_phase":"marketed","molecular_target":"","drug_class":"Sucrose-specific Enzyme [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"investigational-covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 6 months through 4 years of age with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Investigational COVID-19 Vaccine","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"investigational-covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Investigational COVID-19 Vaccine","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"investigational-covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Investigational COVID-19 Vaccine","company_name":"BioNTech","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"benzhydrocodone","indication_name":"Short-term management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BENZHYDROCODONE","company_name":"","drug_phase":"marketed","molecular_target":"Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways","drug_class":"Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic","quality_score":75,"revenue":null,"mechanism":"Benzhydrocodone is a hydrocodone prodrug providing mu-opioid receptor agonism combined with acetaminophen's central analgesic activity."},{"drug_id":"benzhydrocodone","indication_name":"Use in patients for whom alternative treatment options have not been tolerated or are not expected to be tolerated","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BENZHYDROCODONE","company_name":"","drug_phase":"marketed","molecular_target":"Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways","drug_class":"Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic","quality_score":75,"revenue":null,"mechanism":"Benzhydrocodone is a hydrocodone prodrug providing mu-opioid receptor agonism combined with acetaminophen's central analgesic activity."},{"drug_id":"benzhydrocodone","indication_name":"Use in patients for whom alternative treatment options have not provided adequate analgesia or are not expected to provide adequate analgesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BENZHYDROCODONE","company_name":"","drug_phase":"marketed","molecular_target":"Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways","drug_class":"Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic","quality_score":75,"revenue":null,"mechanism":"Benzhydrocodone is a hydrocodone prodrug providing mu-opioid receptor agonism combined with acetaminophen's central analgesic activity."},{"drug_id":"acetazolamide","indication_name":"Anoxia due to high altitude","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diamox","generic_name":"ACETAZOLAMIDE","company_name":"Teva","drug_phase":"marketed","molecular_target":"Carbonic anhydrase","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-kp-2","indication_name":"Prevention of COVID-19 in individuals 6 months through 4 years of age with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi KP.2)","generic_name":"bnt162b2-omi-kp-2","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-kp-2","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi KP.2)","generic_name":"bnt162b2-omi-kp-2","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-kp-2","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older with certain health conditions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi KP.2)","generic_name":"bnt162b2-omi-kp-2","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tazemetostat","indication_name":"Relapsed or Refractory Follicular Lymphoma without Satisfactory Alternatives","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tazverik","generic_name":"tazemetostat","company_name":"Epizyme Inc","drug_phase":"marketed","molecular_target":"Polycomb protein EED","drug_class":"Methyltransferase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Tazverik works by blocking the action of the EED protein, which is involved in the regulation of gene expression."},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"sucraid","indication_name":"Sucrase-isomaltase deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sucraid","company_name":"QOL Medical, LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"sucrase","indication_name":"Sucrase-isomaltase deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sucrase","company_name":"University of Miami","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"calcium-hydrogen-phosphate-dihydrate","indication_name":"General Bone and Joint Health","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dibasic Calcium Phosphate Dihydrate","generic_name":"calcium hydrogen phosphate dihydrate","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"fludrocortisone","indication_name":"Salt-Losing Adrenogenital Syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Florinef","generic_name":"fludrocortisone","company_name":"Generic","drug_phase":"marketed","molecular_target":"Annexin A1, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Mineralocorticoid","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"technetium-tc-99m-exametazime","indication_name":"Detection of altered cerebral perfusion in stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceretec","generic_name":"TECHNETIUM TC 99M EXAMETAZIME","company_name":"GE HealthCare","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"multivitamins","indication_name":"Promote Bone and Dental Health","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"multivitamins","company_name":"Faculdade de Medicina do ABC","drug_phase":"marketed","molecular_target":"","drug_class":"Vitamin C [EPC]","quality_score":17,"revenue":null,"mechanism":null},{"drug_id":"dietary-supplement","indication_name":"Support digestive health","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dietary Supplement","company_name":"Centre for Addiction and Mental Health","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"chlorhexidine-gluconate","indication_name":"Healthcare Personnel Hand Hygiene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CHLORHEXIDINE GLUCONATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"chlorhexidine","indication_name":"Healthcare personnel hand hygiene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exidine","generic_name":"CHLORHEXIDINE","company_name":"Molnlycke Hlth","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 1","drug_class":"chlorhexidine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"potassium-phosphates","indication_name":"Treatment of potassium deficiency (hypokalemia) in patients with hypokalemia due to other health conditions.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Potassium Phosphates","generic_name":"Potassium Phosphate, Dibasic","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Phosphorus homeostasis and cellular biochemical functions","drug_class":"Electrolyte replacement","quality_score":65,"revenue":null,"mechanism":"Phosphate replaces deficient phosphorus for nucleic acid structure, energy storage, cell signaling, and bone mineralization."},{"drug_id":"naloxone-hydrochloride","indication_name":"Pain in patients for whom alternative treatment options are ineffective","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naloxone Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Opioid receptors (mu, kappa)","drug_class":"Mixed opioid agonist-antagonist with opioid antagonist","quality_score":70,"revenue":null,"mechanism":"Pentazocine is a mixed agonist-antagonist at opioid receptors; naloxone is an opioid antagonist."}],"pipeline":[{"drug_id":"dabigatran-etexilate-de","indication_name":"Healthy","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran etexilate (DE)","generic_name":"dabigatran-etexilate-de","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Dabigatran etexilate (DE) as oral capsule","quality_score":null,"revenue":null,"mechanism":"Dabigatran etexilate (DE) as oral capsule"},{"drug_id":"treatment-d","indication_name":"Healthy","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treatment D","generic_name":"treatment-d","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Single 875 mg dose of mevrometostat alternative tablet formulation","quality_score":null,"revenue":null,"mechanism":"Single 875 mg dose of mevrometostat alternative tablet formulation"},{"drug_id":"treatment-b","indication_name":"Healthy","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treatment B","generic_name":"treatment-b","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Single 875 mg dose of mevrometostat alternative tablet formulation","quality_score":null,"revenue":null,"mechanism":"Single 875 mg dose of mevrometostat alternative tablet formulation"},{"drug_id":"treatment-a","indication_name":"Healthy","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treatment A","generic_name":"treatment-a","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Single 875 mg dose of mevrometostat standard tablet formulation","quality_score":0,"revenue":null,"mechanism":"Single 875 mg dose of mevrometostat standard tablet formulation"},{"drug_id":"oligomeric-procyanidin-complex","indication_name":"Energy levels in healthy volunteers","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oligomeric Procyanidin Complex","company_name":"Medical University of South Carolina","drug_phase":"discontinued","molecular_target":"Advanced glycation end products (AGEs), free radicals, inflammatory mediators","drug_class":"Botanical antioxidant, polyphenol","quality_score":null,"revenue":null,"mechanism":"Oligomeric procyanidins are plant-derived polyphenols that exert antioxidant and anti-inflammatory effects, potentially inhibiting advanced glycation end product formation."},{"drug_id":"pf-07314470","indication_name":"Healthy","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07314470","generic_name":"pf-07314470","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"subcutaneous injection","quality_score":null,"revenue":null,"mechanism":"subcutaneous injection"},{"drug_id":"pf-07304814","indication_name":"Healthy","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07304814","generic_name":"pf-07304814","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"PF-07304814 is an anti-viral, formulated for intravenous delivery","quality_score":null,"revenue":null,"mechanism":"PF-07304814 is an anti-viral, formulated for intravenous delivery"},{"drug_id":"niacin","indication_name":"Healthspan improvement","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nicotinic Acid","generic_name":"NIACIN","company_name":"MEDPOINTE PHARM HLC","drug_phase":"marketed","molecular_target":"NAD synthase","drug_class":"Vitamin C [EPC]","quality_score":55,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":163,"totalPipeline":8},"trials":{"data":[{"nct_id":"NCT04321486","title":"Natural History and Patient Journey in Dementia: a Nationwide Linked Electronic Health Records Study of 5.6 Million Individuals.","phase":"","overall_status":"UNKNOWN","enrollment_count":4309481,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT02875327","title":"Linkage of Medicaid Enrollment Information to Surveillance, Epidemiology and End Results Data","phase":"","overall_status":"COMPLETED","enrollment_count":3217145,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04374812","title":"Workforce Hospital Outcomes (in English Acute Hospitals)","phase":"","overall_status":"COMPLETED","enrollment_count":1706388,"lead_sponsor_name":"University of Southampton","has_results":false},{"nct_id":"NCT04670835","title":"Modeling the Impact of Inbound Call Distribution Virtualization in Emergency Medical Communication Centers (EMCCs) on Their Service Level","phase":"","overall_status":"UNKNOWN","enrollment_count":1500000,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT04322786","title":"The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?","phase":"","overall_status":"UNKNOWN","enrollment_count":1302508,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT03144544","title":"Physiological Complexity of Pediatric Surgery Between Types of Hospitals","phase":"","overall_status":"COMPLETED","enrollment_count":830830,"lead_sponsor_name":"The Hospital for Sick Children","has_results":false},{"nct_id":"NCT05010395","title":"Increasing Health Insurance Enrollment Among Uninsured Americans","phase":"NA","overall_status":"COMPLETED","enrollment_count":811795,"lead_sponsor_name":"Office of Evaluation Sciences","has_results":false},{"nct_id":"NCT05386316","title":"The Maternal Health Multilevel Intervention for Racial Equity (MIRACLE) Project","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":540000,"lead_sponsor_name":"Michigan State University","has_results":false},{"nct_id":"NCT06655974","title":"Predictive Modeling for Social Needs in Emergency Department Settings","phase":"NA","overall_status":"COMPLETED","enrollment_count":518512,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT06924580","title":"Early ECG Prediction of Multi-system Disease Cohort Establishment and Follow Up","phase":"","overall_status":"RECRUITING","enrollment_count":500000,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT05621278","title":"Children to Adults Mental and Psychosomatic Health Study (CAMPS)","phase":"","overall_status":"RECRUITING","enrollment_count":400000,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT07375303","title":"Data Mining of Population Health-sub-health-disease Based on Dynamic System Theory","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":380000,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT03602456","title":"Evaluation of the Health and Economic Consequences of Kentucky's Section 1115 Demonstration Waiver","phase":"","overall_status":"TERMINATED","enrollment_count":378828,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT04458350","title":"SNAP Fruit and Vegetable Incentive Program Digital Promotions for Farmers' Markets","phase":"NA","overall_status":"COMPLETED","enrollment_count":251966,"lead_sponsor_name":"Tufts University","has_results":false},{"nct_id":"NCT04735835","title":"Personalized Responses to Dietary Composition Trial 3","phase":"NA","overall_status":"RECRUITING","enrollment_count":250000,"lead_sponsor_name":"Zoe Global Limited","has_results":false},{"nct_id":"NCT03167346","title":"The Investigation of Public Awareness of Core Stroke Symptoms","phase":"","overall_status":"COMPLETED","enrollment_count":243279,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05787548","title":"Reducing Emergency Department Utilization With an After Visit Summary Nudge Toward Alternative Care Options","phase":"NA","overall_status":"COMPLETED","enrollment_count":239841,"lead_sponsor_name":"Geisinger Clinic","has_results":false},{"nct_id":"NCT07382804","title":"Mobile Behavioral Activation Program With Wearable Sensors and Secure Activity Verification","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":227000,"lead_sponsor_name":"Truway Health, Inc.","has_results":false},{"nct_id":"NCT03987633","title":"EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Future Genetics Limited","has_results":false},{"nct_id":"NCT06623799","title":"Impact of Help-Seeking Behaviors on Allergic Rhinitis and Mental Health: A Longitudinal Study","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"QHSLab, Inc.","has_results":false},{"nct_id":"NCT03225586","title":"Prospective Urban Rural Epidemiology Study","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Population Health Research Institute","has_results":false},{"nct_id":"NCT05288023","title":"Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":169707,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT04910750","title":"Tools for the Integrated Management of Childhood Illness (TIMCI): Evaluation of Pulse Oximetry & Clinical Decision Support Algorithms in Primary Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":167517,"lead_sponsor_name":"Swiss Tropical & Public Health Institute","has_results":false},{"nct_id":"NCT03299010","title":"10-year Risk Prediction Models of Complications and Mortality of DM in Hong Kong","phase":"","overall_status":"COMPLETED","enrollment_count":141516,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT06835153","title":"Automatic Feedback Indicator to Enhance the Hospital Discharge Communication Between Acute Care and Primary Care.","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":132000,"lead_sponsor_name":"University Hospital, Grenoble","has_results":false},{"nct_id":"NCT03106727","title":"Evaluating the Impact of a Community Health Worker Program in Neno, Malawi","phase":"NA","overall_status":"COMPLETED","enrollment_count":122395,"lead_sponsor_name":"Partners in Health","has_results":false},{"nct_id":"NCT04323137","title":"Encouraging Flu Vaccination Among High-Risk Patients Identified by ML","phase":"NA","overall_status":"COMPLETED","enrollment_count":117649,"lead_sponsor_name":"Geisinger Clinic","has_results":true},{"nct_id":"NCT03285295","title":"Abbott Laboratories Alinity s Blood Screening Assays - Clinical Evaluation Protocol","phase":"NA","overall_status":"COMPLETED","enrollment_count":106881,"lead_sponsor_name":"Abbott Diagnostics Division","has_results":true},{"nct_id":"NCT05678764","title":"Evaluation of a Conversational Information Collection Tool to Access Talk Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":104874,"lead_sponsor_name":"Limbic Limited","has_results":false},{"nct_id":"NCT07209774","title":"Healthspan Connect Programme of Research","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"King's College London","has_results":false},{"nct_id":"NCT07128966","title":"Direct to Patient Minimal Risk Biospecimen and Data Collection Research","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Joined Bio","has_results":false},{"nct_id":"NCT03762837","title":"Multicenter Prospective Cohort Study of Risk Factors for Gallbladder Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT03938207","title":"Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Taipei Veterans General Hospital, Taiwan","has_results":false},{"nct_id":"NCT05045222","title":"Economic and Clinical Outcomes of (Whole Exome) Sequencing in Tapestry","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03085875","title":"POWERMOM, A Healthy Pregnancy Research Community","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Scripps Translational Science Institute","has_results":false},{"nct_id":"NCT07514377","title":"JiGenerations Health Cohort Study：Parental Exposure and Intergenerational Health in China","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100000,"lead_sponsor_name":"National Research Institute for Family Planning, China","has_results":false},{"nct_id":"NCT05013944","title":"AnovaOS Network Powered Patient Registry","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Anova Enterprises, Inc","has_results":false},{"nct_id":"NCT04187729","title":"Precision Genomics Medicine Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Intermountain Health Care, Inc.","has_results":false},{"nct_id":"NCT04869111","title":"The BrainHealth Project","phase":"NA","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"The University of Texas at Dallas","has_results":false},{"nct_id":"NCT04976829","title":"Evaluating Antibiotic Stewardship Assisted by Computer in the University Hospital of Nancy (MACABAO)","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT05144763","title":"Dynamic CDSA to Manage Sick Children in Tanzania","phase":"NA","overall_status":"COMPLETED","enrollment_count":92331,"lead_sponsor_name":"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland","has_results":false},{"nct_id":"NCT05108831","title":"Dynamic CDSA to Manage Sick Children in Rwanda","phase":"NA","overall_status":"COMPLETED","enrollment_count":85212,"lead_sponsor_name":"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland","has_results":false},{"nct_id":"NCT05311241","title":"Teleconsultation in Ambulatory Care in France","phase":"","overall_status":"COMPLETED","enrollment_count":84000,"lead_sponsor_name":"Les Entreprises de Télémédecine","has_results":false},{"nct_id":"NCT05997836","title":"Behavioral Health Interdisciplinary Program - Collaborative Chronic Care Model (BHIP-CCM) Enhancement Project 2.0","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":81424,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT06131723","title":"UCLA Health Patient Health Tickler Email","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":81000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT06057727","title":"Behavioral Economics to Improve Flu Vaccination Using EHR Nudges","phase":"NA","overall_status":"COMPLETED","enrollment_count":80039,"lead_sponsor_name":"University of Pennsylvania","has_results":true},{"nct_id":"NCT05206643","title":"Shanghai Pudong Cohort","phase":"","overall_status":"UNKNOWN","enrollment_count":80000,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT06454500","title":"Clinical Decision Support to Reduce Catheter Associated Urinary Tract Infections","phase":"NA","overall_status":"COMPLETED","enrollment_count":79369,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT02993965","title":"State Immunization Information Systems to Improve HPV Vaccination Rates","phase":"NA","overall_status":"COMPLETED","enrollment_count":77716,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT07092800","title":"Care Pathways and Disparities in Care for Older Patients With Cancer: Typology, Determinants and Effect on Prognosis ( PASSAGE )","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":75000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}